Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 7, 2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher
GlobeNewswire
·
May 7, 2025
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher Edinburgh, UK, 7 May 2025 - Trogenix Ltd (“Trogenix”), a pioneering biotech company dedicated to developing …
Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*
GlobeNewswire
·
May 7, 2025
The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI- …
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
GlobeNewswire
·
May 7, 2025
SANTA ANA, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer …
Valitor Presents Multiple Preclinical Datasets on the Potential of its Innovative Anti-VEGF Therapy Dosed Twice Yearly for Wet AMD at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
GlobeNewswire
·
May 7, 2025
-VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs -VLTR-559 shown to be more durable, while maintaining potency …
Counslr Partners with Sack the Stigma to Expand Mental Health Wellness Resources
GlobeNewswire
·
May 7, 2025
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Counslr, a leading digital mental health company, and Sack the Stigma, a mental health advocacy organization dedicated to reducing the stigma surrounding mental health challenges within student athletics, …
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
GlobeNewswire
·
May 7, 2025
Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA …
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
GlobeNewswire
·
May 7, 2025
PITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S. Krishnan, …
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …
CorVista Health Announces European Respiratory Journal Publication Detailing Validation of its Non-Invasive Test for Pulmonary Hypertension
GlobeNewswire
·
May 7, 2025
Data demonstrates CorVista’s proprietary machine-learned algorithm detects elevated mean pulmonary artery pressure (mPAP) with strong sensitivity and specificity across diverse patient populations BETHESDA, Md., May 07, 2025 (GLOBE NEWSWIRE) -- CorVista …
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
GlobeNewswire
·
May 7, 2025
WEST CHESTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that …
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting
GlobeNewswire
·
May 7, 2025
Fireside discussion to explore clinical impact of the topline Phase 2 data in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) to be presented at ASCO In-person event and virtual webcast to be held on Saturday, May 31, 2025, at 6:30 pm CDT …
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
GlobeNewswire
·
May 7, 2025
Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker data Clene collecting NfL …
Liberation Labs Announces Manufacturing Partnership with Vivici
GlobeNewswire
·
May 7, 2025
RICHMOND, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Liberation Labs today announced a manufacturing partnership with Dutch ingredients startup Vivici. Liberation Labs will produce Vivici’s flagship ingredient, Vivitein™ BLG, at its Richmond, Indiana facility …
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of …
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference
GlobeNewswire
·
May 7, 2025
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a …
New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
GlobeNewswire
·
May 7, 2025
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data …
PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results
GlobeNewswire
·
May 7, 2025
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced …
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 7, 2025
Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with EPP Plan to initiate Phase 2 study of DISC-3405 in …
ARS Pharmaceuticals’ neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms
GlobeNewswire
·
May 7, 2025
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as little as $25 (if eligible) in preparation for summer travel …
Erasca to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
·
May 7, 2025
SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …